Decreased HbA1c from a mean of 9.5% to 7.5% represents a clinically significant 2 percentage point reduction in glycated haemoglobin — a key marker of long-term blood glucose control in diabetes. This improvement, equivalent to approximately 22 mmol/mol, signals substantially reduced exposure to excess glucose over a sustained period. Understanding what drives this change, which treatments are associated with it, and how to interpret it against NICE targets is essential for both patients and clinicians. This article explores the clinical meaning, associated therapies, guideline context, and the monitoring steps needed to consolidate and build on this important achievement.

What Does a Drop in HbA1c from 9.5% to 7.5% Mean?

A drop from 9.5% to 7.5% represents a 2 percentage point (approximately 22 mmol/mol) absolute reduction in HbA1c, indicating substantially reduced long-term glucose exposure and bringing the patient closer to NICE-recommended targets.

HbA1c — glycated haemoglobin — is a blood test that reflects average blood glucose levels over the preceding two to three months. It is expressed as a percentage (or in mmol/mol under IFCC units) and serves as the primary marker for long-term glycaemic control in people living with diabetes. A reduction in HbA1c from a mean of 9.5% to 7.5% represents a clinically meaningful absolute decrease of 2 percentage points, or approximately 22 mmol/mol.

At 9.5% (approximately 80 mmol/mol), blood glucose levels are significantly elevated, placing individuals at heightened risk of both microvascular and macrovascular complications. Reaching 7.5% (approximately 58 mmol/mol) brings a person considerably closer to the individualised targets recommended by NICE (NG28) for adults with type 2 diabetes. This shift indicates that the body's exposure to excess glucose has been substantially reduced over a sustained period.

It is important to understand that HbA1c does not capture day-to-day glucose variability or hypoglycaemic episodes. In addition, HbA1c results may be unreliable in certain clinical situations — including haemoglobin variants (e.g., sickle cell trait, thalassaemia), recent significant blood loss or transfusion, haemolytic anaemia, and advanced chronic kidney disease (CKD). In these circumstances, clinicians may use alternative markers such as fructosamine, or consider continuous glucose monitoring (CGM) and time-in-range metrics as complementary tools. Nevertheless, as a population-level and individual monitoring tool, a 2% reduction of this magnitude is widely regarded as a significant therapeutic achievement, reflecting improved adherence, effective medication, meaningful lifestyle change, or a combination of all three.

Clinical Significance of This HbA1c Reduction

A 2% HbA1c reduction carries significant protective benefits, including an estimated 37% reduction in microvascular complications and 14% lower myocardial infarction risk per 1% fall, based on UKPDS 35 data.

The clinical importance of reducing HbA1c from 9.5% to 7.5% extends well beyond a laboratory value. Landmark epidemiological data from the UK Prospective Diabetes Study (UKPDS 35, BMJ 2000) demonstrated that each 1% reduction in HbA1c is associated with an approximately 37% reduction in microvascular complications such as diabetic retinopathy, nephropathy, and peripheral neuropathy. A 2% reduction therefore carries substantial potential protective benefit across multiple organ systems, though it is important to note that these are observational associations and individual benefits will vary.

From a cardiovascular perspective, the UKPDS also showed an approximately 14% reduction in myocardial infarction risk per 1% fall in HbA1c, underscoring the systemic benefits of sustained glycaemic improvement. These gains are further enhanced when combined with blood pressure and lipid management, as recommended by NICE NG28.

For patients, this reduction may also translate into tangible symptomatic benefits:

• Reduced thirst and urinary frequency as glucose levels normalise

• Improved energy levels and reduced fatigue

• Lower risk of recurrent infections, including urinary tract and skin infections

• Potential stabilisation or slowing of progression of early-stage diabetic complications

Healthcare professionals should recognise this improvement as an opportunity to reinforce positive behaviour change, review medication appropriateness, and set realistic ongoing targets in partnership with the patient.

Treatments Associated with Lowering HbA1c by Around 2%

Achieving a 2% HbA1c reduction typically requires potent pharmacotherapy such as insulin, GLP-1 receptor agonists, or combination therapy, often alongside structured lifestyle intervention including diet, physical activity, and weight management.

Achieving a 2% reduction in HbA1c typically requires either a potent pharmacological intervention, a combination of agents, or significant lifestyle modification — and often all of these together. Larger absolute reductions are more likely when baseline HbA1c is markedly elevated, as in this case. Several treatment strategies are associated with reductions of this magnitude.

Pharmacological options commonly associated with substantial HbA1c lowering include:

• Metformin: First-line therapy per NICE NG28, typically reducing HbA1c by approximately 1.0–1.5% at therapeutic doses. It works by reducing hepatic glucose output and improving peripheral insulin sensitivity.

• Sulphonylureas (e.g., gliclazide): Associated with HbA1c reductions of approximately 1.0–1.5%, though they carry a risk of hypoglycaemia and weight gain.

• GLP-1 receptor agonists (e.g., semaglutide, liraglutide): These incretin-based therapies stimulate glucose-dependent insulin secretion, suppress glucagon, and slow gastric emptying. Clinical trials have demonstrated HbA1c reductions of approximately 1.0–1.5%, with larger reductions possible from higher baselines, alongside weight loss benefits.

• SGLT-2 inhibitors (e.g., empagliflozin, dapagliflozin): These agents promote urinary glucose excretion and typically reduce HbA1c by approximately 0.5–1.0%. They also carry additional cardiovascular and renal protective effects recognised in NICE NG28, NICE NG203, and relevant NICE technology appraisals.

• DPP-4 inhibitors (e.g., sitagliptin, alogliptin): Generally associated with more modest HbA1c reductions of approximately 0.5–0.8%, with a low risk of hypoglycaemia.

• Pioglitazone: May reduce HbA1c by approximately 0.8–1.4%, though its use requires careful patient selection given its side-effect profile.

• Insulin therapy: Particularly basal insulin regimens, can achieve reductions exceeding 2% in those with markedly elevated baseline HbA1c.

• Dual or triple combination therapy: Combining agents with complementary mechanisms frequently achieves the cumulative reductions seen in this range.

• Bariatric or metabolic surgery: For eligible individuals with obesity and type 2 diabetes, this can produce substantial and sustained HbA1c reductions, as outlined in the NICE obesity pathway.

Lifestyle interventions — including structured dietary programmes, increased physical activity, and weight loss — can independently reduce HbA1c by 1–2%, particularly in the earlier stages of type 2 diabetes. For people with established type 2 diabetes, NHS-endorsed structured education programmes such as DESMOND (Diabetes Education and Self Management for Ongoing and Newly Diagnosed) and X-PERT, as well as the NHS 'Healthy Living for people with type 2 diabetes' digital programme, support sustained behaviour change. Note that the NHS Diabetes Prevention Programme is designed for people at high risk of developing type 2 diabetes ('pre-diabetes'), rather than those with an established diagnosis.

Patients should be advised to report any suspected side effects from their medicines via the MHRA Yellow Card scheme (available at yellowcard.mhra.gov.uk).

NICE Guidelines on Target HbA1c Levels in Type 2 Diabetes

NICE NG28 recommends individualised targets of 48 mmol/mol (6.5%) or 53 mmol/mol (7.0%) for most adults; 58 mmol/mol (7.5%) is a relaxed target reserved for those with frailty, significant comorbidities, or high hypoglycaemia risk.

NICE guidance (NG28, updated 2022) provides clear recommendations on HbA1c targets for adults with type 2 diabetes, emphasising that targets should be individualised based on treatment regimen, comorbidities, risk of hypoglycaemia, and patient preference.

The general NICE-recommended targets are:

• 48 mmol/mol (6.5%): For adults managed by lifestyle and diet alone, or with a single non-hypoglycaemia-inducing drug

• 53 mmol/mol (7.0%): For adults on a drug associated with hypoglycaemia risk (e.g., sulphonylureas or insulin)

• 58 mmol/mol (7.5%): A relaxed target that may be appropriate for selected individuals where tighter control poses unacceptable risks — for example, those with frailty, significant comorbidities, limited life expectancy, or a history of severe hypoglycaemia

It is important to understand that 7.5% (58 mmol/mol) is not a standard target for most adults with type 2 diabetes; rather, it is a relaxed target reserved for specific clinical circumstances. For the majority of patients, targets of 48–53 mmol/mol (6.5–7.0%) remain appropriate depending on their treatment regimen and individual risk profile. Whilst reaching 7.5% from 9.5% is a commendable achievement, clinicians should assess whether further optimisation towards 48–53 mmol/mol is appropriate and safe for the individual.

NICE also advises against pursuing overly aggressive targets in older adults or those with limited life expectancy, where the harms of hypoglycaemia may outweigh the long-term benefits of tighter control.

Regular HbA1c monitoring — typically every three to six months when adjusting treatment, and every six months once stable — is recommended by NICE to guide ongoing management decisions.

Risks and Benefits of Rapid HbA1c Reduction

Rapid HbA1c reduction risks hypoglycaemia and, rarely, early worsening of diabetic retinopathy; a gradual, monitored reduction over 3–6 months offers the best balance of safety and long-term benefit.

Whilst a reduction in HbA1c from 9.5% to 7.5% is broadly beneficial, the rate at which this improvement occurs warrants careful clinical consideration. Rapid normalisation of blood glucose — particularly when achieved through insulin or sulphonylureas — carries specific risks that must be balanced against the long-term gains.

Potential risks of rapid HbA1c reduction include:

• Hypoglycaemia: The most immediate concern, particularly in patients on insulin or sulphonylureas. Symptoms include sweating, tremor, palpitations, confusion, and, in severe cases, loss of consciousness. Patients should be educated on the recognition and management of hypoglycaemic episodes, and advised to avoid recurrent hypoglycaemia.

• Impaired hypoglycaemia awareness: Repeated hypoglycaemic episodes can blunt the body's hormonal and symptomatic warning responses, making it harder for patients to recognise low blood sugar. This is distinct from the process of glucose normalisation itself. Structured education and regular clinical review can help identify and address impaired awareness.

• Early worsening of diabetic retinopathy: There is evidence — primarily from the DCCT trial in type 1 diabetes — that very rapid glycaemic improvement can paradoxically worsen pre-existing retinopathy in the short term in a small proportion of patients. This phenomenon is less well characterised in type 2 diabetes. Clinicians should ensure that annual NHS Diabetic Eye Screening Programme (DESP) review is up to date, and should not routinely delay needed glycaemic optimisation on this basis. Prompt ophthalmological review is appropriate if new visual symptoms develop or if significant pre-existing retinopathy is already known.

Benefits, however, are well established and include the microvascular and macrovascular risk reductions outlined above. For most patients, a gradual, sustained reduction over three to six months — guided by regular monitoring and clinical review — offers the optimal balance of efficacy and safety. Patients should be encouraged to report any new or unusual symptoms to their GP or diabetes care team promptly.

Monitoring and Next Steps After Improving Glycaemic Control

After HbA1c improvement, NICE recommends repeat HbA1c every 3–6 months, plus annual renal function, retinal screening, foot examination, and ongoing cardiovascular risk management to consolidate gains.

Achieving a meaningful reduction in HbA1c is an important milestone, but it marks the beginning of an ongoing management process rather than a conclusion. Once glycaemic control has improved, a structured review should be undertaken to consolidate gains and identify any further optimisation opportunities.

Key monitoring steps following HbA1c improvement include:

• Repeat HbA1c at three to six months to confirm sustained control and assess whether further titration is needed; once stable, every six months in line with NICE NG28

• Renal function, eGFR, and urine albumin-to-creatinine ratio (ACR) — annual assessment is recommended; dose adjustments to metformin or SGLT-2 inhibitors may be required at lower eGFR thresholds per NICE NG28 and NG203

• Blood pressure and lipid profile — cardiovascular risk management remains integral to diabetes care

• Retinal screening — annual diabetic eye screening via the NHS Diabetic Eye Screening Programme should continue; expedite review if new visual symptoms arise or if significant pre-existing retinopathy is present

• Foot examination — annual structured foot assessment to detect early neuropathy or vascular changes, with referral to the Foot Protection Service or Multidisciplinary Foot Care Service as indicated by risk classification, in line with NICE NG19

• Weight and BMI — particularly relevant if GLP-1 receptor agonists or lifestyle changes have contributed to the improvement

Patients should be advised to contact their GP or diabetes nurse if they experience:

• Frequent or severe hypoglycaemic episodes

• Unexpected weight loss or gain

• New visual disturbances

• Signs of infection or poor wound healing

Ongoing structured diabetes education — such as DESMOND, X-PERT, or the NHS 'Healthy Living for people with type 2 diabetes' programme — peer support, and access to a multidisciplinary team including dietitians, podiatrists, and specialist nurses are all recommended by NICE to sustain long-term glycaemic improvements and support overall wellbeing. Patients should also be reminded that suspected side effects from any medicines can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Experiencing these side effects? Our pharmacists can help you navigate them →

Frequently Asked Questions